Brainstem Glioma, Diffuse Intrinsic Pontine Glioma
Conditions
Keywords
diffuse intrinsic pontine glioma, DIPG, childhood brainstem glioma, pediatric brainstem glioma, brainstem glioma, BSG
Brief summary
The purpose of this study is to prospectively collect specimens from pediatric patients with diffuse intrinsic pontine glioma or brainstem glioma, either during therapy or at autopsy, in order to characterize the molecular abnormalities of this tumor.
Detailed description
High grade diffuse intrinsic pontine glioma (DIPG) accounts for approximately 80% of pediatric brainstem tumors and 10% of pediatric brain tumors, and is the most lethal form of brainstem gliomas in children. There is currently no effective therapy to treat these tumors. We hypothesize that this tumor exhibits unique molecular abnormalities leading to altered RNA and protein expression. The aim of this trial is to collect specimens from pediatric patients with diffuse intrinsic pontine glioma including serum, cerebrospinal fluid, urine, brain tumor and other constitutional tissue, during therapy and/or at autopsy. Our goal is to study this tissue to characterize the genetic abnormalities that lead to tumor formation in order to identify key molecules as biomarkers which we can target to design and test new and more effective treatments.
Interventions
None listed
Sponsors
Children's National Research Institute
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 21 Years
Healthy volunteers
No
Inclusion criteria
* Patients of any age with clinical and radiologic diagnosis of diffuse intrinsic pontine glioma * Patients with other high-grade gliomas originating in the brainstem * Patients with focal gliomas (WHO grade I/II) of the brainstem
Exclusion criteria
* Patients with any type of infiltrative low grade (WHO grade I and II) or high grade glioma (WHO grade III and IV) originating outside the brainstem * Patients harboring primary brainstem tumors with other histologic diagnoses (e.g., PNET)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proteomic profiling of tumor, normal brainstem tissue and cerebrospinal fluid | 5 years | To obtain full characterization of collected samples, proteomic profiling will be done on tumor and normal samples collected. |
| Genome-wide expression patterns of RNA in tumor samples, normal brainstem tissue and cerebrospinal fluid using Affymetrix gene expression profiling | 5 years | Collected tumor and normal samples will potentially be used for RNA genome-wide expression pattern profiling. |
| Validation of results of the genome-wide analysis | 5 years | The molecular analysis done on collected samples will be validated through whole genome sequencing. |
| In vitro and in vivo molecular analysis of collected samples | 5 years | Collected samples will potentially be used for in vitro analysis and generation of animal models of this tumor. |
| Protein expression patterns as assessed by immunohistochemistry and western blot compared to normal brainstem tissue | 5 years | Collected tumor and normal samples will have the immunochemistry and western blot compared to assess protein expression variation. |
| Genome-wide analysis of tumor samples and normal brainstem tissue | 5 years | To obtain full characterization of collected samples, whole genome sequencing will be done on tumor and normal samples collected. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assess aspects associated with specimen acquisition, including potential benefits and drawbacks | 5 years | In an effort to continue to draw knowledge from samples collected, potential benefits and drawbacks from specimen acquisition will be continuously accessed. |
Countries
United States
Contacts
Primary ContactJavad Nazarian, PhD
Backup ContactCaroline Kopsidas, BS
Outcome results
None listed